PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Aribio Holdings, rooted in the former LED lighting maker Solux, remains the largest shareholder of unlisted drug developer Aribio after the two firms withdrew their merger in late September, and now awaits the Phase 3 topline results for Alzheimer's candidate AR1001.
On September 29, 2026, Aribio Holdings and Aribio terminated their merger agreement, again halting the attempt to bring Aribio onto KOSDAQ via merger.
Aribio signed a global exclusive licensing deal with China's Fosun Pharma for AR1001 worth up to $4.7 billion (about KRW 7 trillion) and has already received roughly KRW 90 billion in option fees.
The global Phase 3 trial POLARIS-AD for AR1001 completed its final patient dosing in late June, with detailed results scheduled for the opening session of CTAD 2026 on November 16.
The core LED lighting business saw consolidated revenue fall for two straight years, from KRW 59.8 billion in 2023 to KRW 38.3 billion in 2025, while remaining in operating losses.
Consolidated net income has shown large quarter-to-quarter swings disconnected from operating profit, turning positive in Q4 2025 and Q2 2026 apparently due to non-operating items.
Aribio Holdings traces back to Solux, an LED lighting manufacturer founded in 1996 that listed on KOSDAQ in November 2020.
The company offers a range of indoor, outdoor and special-purpose lighting products, with major customers including large construction firms such as Hyundai Engineering & Construction and Daewoo Engineering & Construction, along with public entities like Korea Expressway Corporation and Korea Hydro & Nuclear Power.
It has recently expanded beyond its traditional B2B and B2G focus into the B2C lighting market, pursuing sales growth through offline channels such as large marts and online distribution.
The company is also developing DC lighting technology linked directly to distributed power sources like solar and energy storage systems, while cultivating human-centric lighting (HCL) and bio-therapy lighting as a lighting-bio convergence growth axis.
Separate from its lighting and electrical business, the company serves as the largest shareholder of unlisted drug developer Aribio, functioning much like a group holding company.
Aribio is developing the oral Alzheimer's disease candidate AR1001, and has completed a region-by-region licensing structure: Samjin Pharm holds Korean rights, Neuco United and Fosun Pharma cover China and ASEAN, UAE-based Arcera covers the Middle East, Latin America, Africa and the CIS, and Fosun Pharma holds rights to the remaining major global markets including Europe, North America and Japan.
In March 2026 the group acquired control of vaccine and animal-drug developer Cha Vaccine Institute and invested in Aribio Lab, expanding its affiliate portfolio.
Although the merger agreement between Aribio Holdings and Aribio was terminated in late September, Holdings' status as Aribio's largest shareholder and its role within the group remain unchanged.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩9.8B | -₩2.8B | −28.6% |
| 2025Q3 | ₩7.9B | -₩2.4B | −30.9% |
| 2025Q4 | ₩15.5B | ₩300M | 2.2% |
| 2026Q1 | ₩7.4B | -₩3.1B | −41.6% |
| 2026Q2 | ₩10.7B | -₩2.8B | −25.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩55.9B | -₩4.3B | -₩4.3B | −7.7% | −10.0% | 57.8% |
| 2023 | ₩59.8B | ₩500M | -₩6.7B | 0.9% | −10.7% | 156.6% |
| 2024 | ₩50.7B | -₩6.6B | -₩41B | −13.1% | −52.3% | 49.7% |
| 2025 | ₩38.3B | -₩6.7B | -₩7.7B | −17.6% | −8.5% | 55.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Aribio Holdings' consolidated revenue edged up from KRW 55.9 billion in 2022 to KRW 59.8 billion in 2023, but then declined for two straight years to KRW 50.7 billion in 2024 and KRW 38.3 billion in 2025.
Operating profit was positive only in 2023 at KRW 0.5 billion, while remaining in losses of KRW -4.3 billion in 2022, KRW -6.6 billion in 2024 and KRW -6.7 billion in 2025.
Net income attributable to owners widened sharply from KRW -4.3 billion in 2022 and KRW -6.7 billion in 2023 to KRW -41.0 billion in 2024, before narrowing to KRW -7.7 billion in 2025.
The quarterly pattern shows a notable gap between operating results and net income: in Q2 2025 (revenue KRW 9.8 billion, operating loss KRW -2.8 billion) and Q3 2025 (revenue KRW 7.9 billion, operating loss KRW -2.4 billion), net losses of KRW -13.6 billion and KRW -7.1 billion were far larger than operating losses, while in Q4 2025, despite modest revenue of KRW 15.5 billion and a small operating profit of KRW 0.3 billion, net income reached KRW 17.9 billion, suggesting a large non-operating gain not explained by operating results alone.
In 2026, Q1 losses widened again (revenue KRW 7.4 billion, operating loss KRW -3.1 billion, net loss KRW -8.5 billion), while Q2 saw revenue of KRW 10.7 billion and an operating loss of KRW -2.8 billion but a net profit of KRW 11.2 billion, continuing the volatile pattern.
This trajectory appears to reflect a mix of weak profitability in the core LED lighting segment and irregular non-operating items likely tied to Aribio-related equity or licensing arrangements.
On the balance sheet, the debt ratio spiked to 156.6% in 2023, fell sharply to 49.7% in 2024, and edged up to 55.8% in 2025, while total equity rose every year, from KRW 43.3 billion in 2022 to KRW 90.9 billion in 2025.
Operating cash flow was a positive KRW 15.7 billion in 2022 but turned negative for three consecutive years from 2023 to 2025 (KRW -3.7 billion, -6.5 billion, -2.7 billion), indicating the core business's cash-generating capacity has yet to recover.
Because the company spans two unrelated businesses—LED lighting and Alzheimer's drug development—industry analysis must be split accordingly.
The domestic LED lighting market is largely mature, with growth increasingly driven by value-added convergence technologies such as smart lighting, DC lighting and human-centric lighting rather than simple replacement demand.
Revenue tends to be volatile given its dependence on construction activity and public procurement volumes, and many competitors share a similar B2B/B2G revenue structure.
The Alzheimer's treatment market, by contrast, is highly competitive among major pharmaceutical companies amid a growing patient population from aging demographics.
Existing approved anti-amyloid injectable therapies have faced safety concerns such as brain swelling and microbleeding (ARIA) as well as accessibility constraints from intravenous administration, which are being positioned as differentiating points for the oral candidate AR1001.
Even before its Phase 3 topline announcement, Aribio had already built a region-by-region commercialization network through licensing agreements with Samjin Pharm, Arcera and Fosun Pharma worth a cumulative total of roughly KRW 10 trillion.
It should be noted, however, that most of this contract value consists of milestones and royalties contingent on clinical success, with confirmed cash received so far limited to an upfront option-fee portion.
The company's biggest near-term variable is the Phase 3 topline result for AR1001. Aribio completed the final patient's 52-week dosing on June 29 and has targeted announcing topline results as early as September or by October at the latest.
Detailed clinical results are scheduled to be unveiled in the opening-day oral presentation session of the CTAD 2026 conference in Boston on November 16-19, with the presentation to be delivered by Stanford University's Dr. Sharon Sha, the trial's global lead principal investigator.
The company has said that after the topline announcement, Aribio will directly lead preparation of the FDA new drug application package, while Fosun Pharma supports manufacturing, supply chain, and regulatory and commercialization efforts across countries.
Following the merger withdrawal, the company has set expanding its own business and enhancing the value of its Aribio stake as its two pillars, with detailed growth strategy to be unveiled at the Aribio Group vision declaration event on October 1.
Co-CEO Seong Su-hyun has said the company is reviewing multiple value-enhancement paths beyond merger, including a standalone listing and even a potential move to the KOSPI market.
In the LED lighting segment, revenue diversification is being pursued through B2C market entry and overseas supply and local manufacturing partnerships.
Aribio Holdings' market value should be understood as reflecting both the core LED lighting business and the potential value of its stake in unlisted drug developer Aribio.
While net income over the most recent four reported quarters aggregates to a positive figure, as noted earlier this appears driven more by irregular non-operating items than by operating performance, warranting caution in assessing earnings quality.
The price-to-book multiple shows somewhat divergent readings depending on whether book value per share is calculated internally or on an exchange-reported basis, though both bases sit in a range reflecting a premium over net assets.
There has been no dividend payment history in recent years, limiting the investment appeal from a dividend perspective.
The share price fell sharply for two consecutive days immediately after the merger-withdrawal disclosure in late September, underscoring high sensitivity to news flow and the structural tendency for expectations and disappointments tied to the unlisted affiliate's equity value to be reflected almost immediately in the stock.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Even before its Phase 3 results were announced, Aribio had sequentially signed exclusive regional licensing deals with Samjin Pharm, Arcera and Fosun Pharma, bringing the cumulative contract value to roughly KRW 10 trillion.
Of this, about KRW 90 billion has already been received in cash as option fees, easing much of the clinical funding burden. If the trial succeeds, additional milestones and sales royalties of up to 20% could also be secured.
Unlike existing anti-amyloid injectable therapies, AR1001 is a once-daily oral pill viewed as carrying relatively lower ARIA-related safety concerns.
Its multi-mechanism, disease-modifying concept has drawn interest from a number of clinical experts, and academic attention has grown further with its selection for the opening oral-presentation session at CTAD 2026.
Despite the merger's withdrawal, Aribio Holdings retains its status as Aribio's largest shareholder, leaving room for future clinical and business progress at Aribio to be reflected in the value of that stake.
The company has said it is reviewing multiple value-enhancement paths, including a standalone listing or a move to KOSPI. Insider buying has also been reported, including an open-market purchase by Vice Chairman Seong Su-hyun.
The merger between Aribio Holdings and Aribio was ultimately withdrawn after the reference share price fell well below the share buyback claim price, raising the risk of large-scale appraisal-rights exercise.
Aribio had previously attempted and failed at technology-special listings three times, reaffirming uncertainty around its listing and merger process. Delays in restructuring governance and unresolved backdoor-listing controversies have also been flagged as a burden on restoring minority shareholder trust.
Consolidated revenue fell for two straight years, from KRW 59.8 billion in 2023 to KRW 38.3 billion in 2025, while operating results reverted from a slight profit in 2023 to consecutive losses in 2024 and 2025.
Operating cash flow has also been negative for three consecutive years from 2023 to 2025, delaying recovery of the core business's cash-generating capacity. Given a revenue structure closely tied to construction activity and public procurement, recurring swings in performance tied to sector conditions remain possible.
AR1001's Phase 3 topline results have not yet been disclosed, and a below-expectation outcome could jeopardize the realization of milestones and royalties under the existing licensing agreements. Even the company's special advisor has noted that funding is still needed, pointing to ongoing capital-raising requirements.
Financial strain from affiliate expansion also persists, as a substantial portion of the payment for the Cha Vaccine Institute stake was funded through convertible bond issuance.
The final statistical analysis of AR1001's Phase 3 trial has not yet been announced, and the possibility that efficacy or safety readouts fall short of expectations cannot be ruled out. The timing and size of milestone payments under the already-signed licensing agreements could shift depending on the topline outcome.
There is also a risk of schedule delays, such as additional data requests, during regulatory discussions with agencies like the FDA.
Repeated cycles of pursuing and then withdrawing the merger have involved correction requests from the Financial Supervisory Service and unfaithful-disclosure designation issues, leaving market concerns about disclosure reliability.
The structure in which the controlling shareholder is involved in managing both Aribio Holdings and Aribio warrants scrutiny for potential conflicts of interest. Terms of any future merger attempt or inter-affiliate transactions also require ongoing monitoring from a minority shareholder perspective.
The LED lighting segment has posted operating losses and negative operating cash flow for two consecutive years, limiting its own cash-generating capacity. Convertible bonds have been used to fund affiliate acquisitions, creating potential equity dilution upon future conversion.
Reliance on external funding may continue until license-related income from the biotech segment materializes on a larger scale.
At the Aribio Group vision declaration event, the group's post-merger-withdrawal operating direction and individual growth strategies for Aribio Holdings, Aribio and Aribio Lab are to be unveiled.
Watch for the AR1001 Phase 3 topline announcement that Aribio has targeted for this window; delays or results diverging from expectations could affect the timing of milestone realization under the licensing agreements.
At CTAD 2026 in Boston, detailed 52-week efficacy and safety data for AR1001 will be presented in the opening oral session.
The Q3 2026 quarterly report, due within 45 days of quarter-end under the Capital Markets Act, will show how the lighting segment's results and cost structure have evolved since the merger withdrawal.
Check whether Fosun Pharma exercises its option and whether Aribio receives the additional $80 million (about KRW 120 billion) payment.
Aribio Holdings combines two unrelated pillars: its legacy LED lighting business and the value of its stake in unlisted drug developer Aribio, of which it remains the largest shareholder.
The late-September withdrawal of the merger halted, for now, the attempt to combine both businesses into a single listed entity, but Holdings' control over Aribio remains intact.
While the core LED lighting segment has yet to escape two straight years of declining revenue and operating losses, Aribio has completed its Phase 3 trial and secured cumulative global licensing agreements worth roughly KRW 10 trillion as it prepares for commercialization.
The quarterly net income volatility disconnected from operating results observed in the consolidated financials appears to reflect this dual business structure.
Key items to watch ahead include the AR1001 Phase 3 topline result, the November CTAD presentation, and the growth strategy Holdings itself is set to unveil at its October vision declaration event. This report is provided for informational purposes only and does not constitute a buy or sell recommendation.
Report written 2026-10-01 · Data as of 2026-09-30
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.